Clinical Trial News and Research

RSS

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.

19 May 2011

Aspirin, simvastatin not effective in combating pulmonary artery hypertension

Despite their beneficial effects in treating heart disease, neither aspirin nor simvastatin appear to offer benefit to patients suffering from pulmonary artery hypertension (PAH), according to a National Institutes of Health (NIH)-funded study conducted at four U.S. medical centers. This was the first NIH-funded randomized clinical trial (RCT) in PAH.

19 May 2011

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to new research from The University of Texas MD Anderson Cancer Center.

19 May 2011

New insight into skin hardening syndromes

Researchers from Boston University School of Medicine have discovered new details about the underlying mechanisms of skin hardening syndromes.

18 May 2011

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Data on the use of denosumab (Xgeva) to improve bone metastases-free survival in men with high-risk prostate cancer was presented at the American Urological Association conference today for the first time.

18 May 2011

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Micromet, Inc. today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive acute lymphoblastic leukemia were published in the May 16th on-line edition of the Journal of Clinical Oncology.

18 May 2011

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.

18 May 2011

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin, during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C.

18 May 2011

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.

18 May 2011

$Avedro completes two Phase III corneal cross-linking studies in keratoconus, ectasia post-refractive surgery$

Avedro completes two Phase III corneal cross-linking studies in keratoconus, ectasia post-refractive surgery

Avedro, Inc. today announced the completion of all one-year follow-up visits for patients enrolled in its two multi-center Phase III studies evaluating the safety and efficacy of corneal collagen cross-linking for the treatment of progressive keratoconus and ectasia following refractive surgery.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

Anavex comments on new Alzheimer’s disease diagnostic guidelines

Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and the Alzheimer’s Association, which have been updated for the first time in more than 25 years. The new guidelines discuss the importance of new technologies, including brain imaging and biomarker analysis, in research and clinical diagnosis. They describe Alzheimer’s disease at a preclinical stage, Mild Cognitive Impairment (MCI) due to Alzheimer’s disease, and dementia due to Alzheimer’s pathology.

18 May 2011

CryoLife acquires Cardiogenesis

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has successfully completed its acquisition of Cardiogenesis Corporation.

17 May 2011

Pernix first quarter net revenues increase 14% to $10.1 million

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company primarily focused on the pediatric market, today announced financial results for the first quarter of 2011.

17 May 2011

Early exposure to social deprivation and neglect linked to prematurely shortened telomeres in children

Studies in institutionalized Romanian children have found that the length of time spent in conditions of social deprivation and neglect correlates with lower IQ and behavioral problems. A new study, led by researchers at Children's Hospital Boston and Tulane University, shows that early adversity even affects children's chromosomes – prematurely shortening the chromosome tips, known as telomeres, and hastening how quickly their cells "age."

17 May 2011

Pfizer seeks U.S. FDA, Japanese MHLW approval for crizotinib NDA to treat ALK-positive advanced NSCLC

Pfizer Inc. announced today that its New Drug Application for crizotinib, an oral first-in-class anaplastic lymphoma kinase inhibitor, has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration and has been filed with the Japanese Ministry of Health, Labour and Welfare.

17 May 2011

Medtronic to present clinical trial data of IN.PACT drug-eluting balloon technology at EuroPCR meeting

A global leader in advancing the treatment of cardiovascular disease through innovative medical technology, Medtronic, Inc. today announced recent milestones in its clinical program for the IN.PACT drug-eluting balloon technology.

From Medtronic 17 May 2011

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Teva Pharmaceutical Industries Ltd. and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody.

17 May 2011

Phase 2 trial data of PET myocardial perfusion imaging with flurpiridaz F 18 presented at ICNC10

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced data from a Phase 2 clinical trial that demonstrated Positron Emission Tomography myocardial perfusion imaging with flurpiridaz F 18 provided superior image quality, diagnostic certainty and diagnostic performance for detecting coronary artery disease (CAD) compared to single photon emission computed tomography myocardial perfusion imaging, the current standard for the non-invasive detection of CAD.

17 May 2011

CytRx sells global rights of molecular chaperone assets to Orphazyme

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has sold the worldwide rights to its molecular chaperone assets to privately-held, Copenhagen, Denmark-based Orphazyme ApS.

17 May 2011

Clinical Trial News and Research

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Aspirin, simvastatin not effective in combating pulmonary artery hypertension

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

New insight into skin hardening syndromes

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Avedro completes two Phase III corneal cross-linking studies in keratoconus, ectasia post-refractive surgery

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

Anavex comments on new Alzheimer’s disease diagnostic guidelines

CryoLife acquires Cardiogenesis

Pernix first quarter net revenues increase 14% to $10.1 million

Early exposure to social deprivation and neglect linked to prematurely shortened telomeres in children

Pfizer seeks U.S. FDA, Japanese MHLW approval for crizotinib NDA to treat ALK-positive advanced NSCLC

Medtronic to present clinical trial data of IN.PACT drug-eluting balloon technology at EuroPCR meeting

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Phase 2 trial data of PET myocardial perfusion imaging with flurpiridaz F 18 presented at ICNC10

CytRx sells global rights of molecular chaperone assets to Orphazyme

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News